ReviewJournal of translational medicine2012
IL-12 based gene therapy in veterinary medicine.
Review in Journal of translational medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Human immuno-therapeutics for cancer treatment of dogs?Frontiers in veterinary science · 2025Review
- Prior corticosteroid treatment alters cPBMC composition and IFNγ response to immunotherapy in canine cancer.Frontiers in immunology · 2025Article
- Comparative oncology in action: vignettes on immunotherapy development.Veterinary oncology (London, England) · 2025Review
- Epigenetic and gene therapy in human and veterinary medicine.Environmental epigenetics · 2024Review
- Meeting Contemporary Challenges: Development of Nanomaterials for Veterinary Medicine.Pharmaceutics · 2023Review
- Tumor cell-based vaccine contributes to local tumor irradiation by eliciting a tumor model-dependent systemic immune response.Frontiers in immunology · 2022Article
- Brief in vitro IL-12 conditioning of CD8Cancer immunology, immunotherapy : CII · 2021Review
- Review
- Tumor perfusion evaluation using dynamic contrast-enhanced ultrasound after electrochemotherapy and IL-12 plasmid electrotransfer in murine melanoma.Scientific reports · 2021Article
- Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs.Cancers · 2021Article
- Safety and interim survival data after intracranial administration of M032, a genetically engineered oncolytic HSV-1 expressing IL-12, in pet dogs with sporadic gliomas.Neurosurgical focus · 2021Article
- Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus.Journal of translational genetics and genomics · 2021Article
- Results of Dynamic Contrast-Enhanced Ultrasound Correlate With Treatment Outcome in Canine Neoplasia Treated With Electrochemotherapy and Interleukin-12 Plasmid Electrotransfer.Frontiers in veterinary science · 2021Article
- The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas.Frontiers in surgery · 2020Article
- Electroporation-Based Treatments in Small Animal Veterinary Oral and Maxillofacial Oncology.Frontiers in veterinary science · 2020Review
- A Novel Method for Controlled Gene Expression via Combined Bleomycin and Plasmid DNA Electrotransfer.International journal of molecular sciences · 2019Article
- Intratumoral expression using a NFkB-based promoter enhances IL12 antitumor efficacy.Cancer gene therapy · 2019Article
- A Review of Immunotherapeutic Strategies in Canine Malignant Melanoma.Veterinary sciences · 2019Review
- Tumor cell death after electrotransfer of plasmid DNA is associated with cytosolic DNA sensor upregulation.Oncotarget · 2018Article
- Efficient expression of bioactive murine IL12 as a self-processing P2A polypeptide driven by inflammation-regulated promoters in tumor cell lines.Cancer gene therapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of large animals as an experimental model for novel treatment techniques has many advantages over the use of laboratory animals, so veterinary medicine is becoming an increasingly important translational bridge between preclinical studies and human medicine. The results of preclinical studies show that gene therapy with therapeutic gene encoding interleukin-12 (IL-12) displays pronounced antitumor effects in various tumor models. A number of different studies employing this therapeutic plasmid, delivered by either viral or non-viral methods, have also been undertaken in veterinary oncology. In cats, adenoviral delivery into soft tissue sarcomas has been employed. In horses, naked plasmid DNA has been delivered by direct intratumoral injection into nodules of metastatic melanoma. In dogs, various types of tumors have been treated with either local or systemic IL-12 electrogene therapy. The results of these studies show that IL-12 based gene therapy elicits a good antitumor effect on spontaneously occurring tumors in large animals, while being safe and well tolerated by the animals. Hopefully, such results will lead to further investigation of this therapy in veterinary medicine and successful translation into human clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.